Core Viewpoint - The stock of Shuoshi Biotechnology fell nearly 15% in the afternoon, with several other companies including Anglikang, Wanbangde, Kanglong Huacheng, Meidixi, Haoyuan Pharmaceutical, Jindike, and Jinshiyao also experiencing declines of over 5% [1] Company Performance - Shuoshi Biotechnology's stock decline of nearly 15% indicates significant market volatility [1] - Other companies in the sector, such as Anglikang and Wanbangde, also faced notable stock price drops, suggesting a broader trend affecting multiple firms [1] - The overall performance of the biotechnology sector appears to be under pressure, as indicated by the collective decline of several key players [1]

可資比較公司及佰翱得的各估值詳情概述如下： 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Pharmaron Beijing Co., Ltd. 康 龍 化 成（ 北 京 ）新 藥 技 術 股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：3759） 補充公告 有關收購佰翱得82.54%股份構成關連交易 茲提述本公司日期為2025年10月28日內容有關收購佰翱得82.54%股份的公告 （「該公告」）。除另有界定者外，本公告所用詞彙與該公告所用者具有相同涵義。 除該公告所披露的資料外，本公司謹此提供有關本公司達致本次收購的對價時所 考慮因素的其他詳情。 於釐定本次收購的對價時，本公司已基於其對CRO服務市場的了解及其自身於該 業務的經驗，對佰翱得進行全面估值。誠如該公告所披露，本公司透過與在同行 業經營的四家可資比較公司進行比較而達致其對佰翱得的估值，該等公司均已上 市，就比較而言可提供公開可得且可靠的財務數據。下文概述 ...

Pharmaron Beijing Co., Ltd. 康 龍 化 成（ 北 京 ）新 藥 技 術 股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：3759） 補充公告 有關收購佰翱得82.54%股份構成關連交易 茲提述本公司日期為2025年10月28日內容有關收購佰翱得82.54%股份的公告 （「該公告」）。除另有界定者外，本公告所用詞彙與該公告所用者具有相同涵義。 除該公告所披露的資料外，本公司謹此提供有關本公司達致本次收購的對價時所 考慮因素的其他詳情。 於釐定本次收購的對價時，本公司已基於其對CRO服務市場的了解及其自身於該 業務的經驗，對佰翱得進行全面估值。誠如該公告所披露，本公司透過與在同行 業經營的四家可資比較公司進行比較而達致其對佰翱得的估值，該等公司均已上 市，就比較而言可提供公開可得且可靠的財務數據。下文概述所有經選定可資比 較公司的主要營業地點位於中國，並經營與佰翱得業務相似的CRO業務，且均為 上市公司中業務最接近佰翱得業務的上市公司。由於市銷率及市盈率是評估CRO 業務常用的財務指標，因此我們在對佰翱得的全面估值中參考該等可資比較公司 的市銷率及市盈率 ...

Group 1 - The core viewpoint indicates a decline in innovative drug concept stocks, with notable drops in companies such as Kanglong Chemical, Kelun Pharmaceutical, and Xinlitai, among others [1] - The innovative drug-related ETFs have also experienced a decline, with an overall drop exceeding 2% [1] - Despite the downturn, there have been positive developments in China's biotechnology sector, including 35 research presentations at the ESMO 2025 conference and significant collaborations like the $11.4 billion partnership between Innovent Biologics and Takeda, highlighting global recognition of Chinese innovative drug value [2]

Group 1 - Kanglong Chemical (03759.HK) has seen a decline of over 5% in its stock price, with a cumulative drop exceeding 15% within the month [1] - As of the latest update, the stock is down 5.41%, trading at 22.04 HKD, with a transaction volume of 129 million HKD [1]

华西证券（002926）此前发布研报称，公司三季度业绩符合预期，新签订单呈现加速趋势展望未来，考 虑到订单呈现快速增长，以及继续降本增效，及公司维持25年收入指引为12%~16%，判断未来业绩将 呈现边际改善趋势。 消息面上，康龙化成发布股份减持公告，合计持股14.17%的公司股东深圳市信中康成投资合伙企业(有 限合伙)(简称"信中康成")及其一致行动人深圳市信中龙成投资合伙企业(有限合伙)计划合计减持公司股 份不超过2667.29万股，占公司总股本的1.5%。 康龙化成（300759）(03759)现跌超5%，月内累计跌幅已超15%。截至发稿，跌5.41%，报22.04港元， 成交额1.29亿港元。 ...

Core Viewpoint - 康龙化成's stock has experienced a significant decline, dropping over 5% in a single day and more than 15% in the month, attributed to a share reduction announcement by major shareholders [1] Group 1: Stock Performance - 康龙化成's stock price is currently at 22.04 HKD, reflecting a decrease of 5.41% [1] - The total trading volume for the stock reached 1.29 billion HKD [1] Group 2: Shareholder Actions - Major shareholders, 深圳市信中康成投资合伙企业 and its acting party, plan to reduce their holdings by up to 26.67 million shares, which represents 1.5% of the total share capital [1] Group 3: Company Performance Outlook - 华西证券 reported that 康龙化成's Q3 performance met expectations, with new orders showing an accelerating trend [1] - The company maintains a revenue growth guidance of 12% to 16% over the next 25 years, indicating a potential for marginal improvement in future performance [1]

Group 1 - The core point of the article is that shareholders of Kanglong Chemical intend to reduce their holdings, leading to a decline in both A-shares and H-shares, which fell over 5% and reached new lows since mid-September [1] - The shareholders, Shenzhen Xincheng Kangcheng Investment Partnership and Shenzhen Xincheng Longcheng Investment Partnership, plan to reduce their holdings by up to 26.6729 million shares, accounting for no more than 1.5% of the company's total share capital [1] - The company has announced a total of four share reduction plans in the past three years, indicating a pattern of shareholder divestment [1]

Core Viewpoint - Kanglong Chemical experienced a decline of 5.02% on November 17, with a stock price of 29.90 yuan per share and a total market capitalization of 53.168 billion yuan [1] Company Overview - Kanglong Chemical (Beijing) New Drug Technology Co., Ltd. was established on July 1, 2004, and went public on January 28, 2019. The company is located in Beijing Economic and Technological Development Zone [1] - The main business segments include laboratory services (60.43%), CMC (small molecule CDMO) services (21.58%), clinical research services (14.58%), and large molecule and cell & gene therapy services (3.28%) [1] Fund Holdings - The Xinda Australia Fund has a significant holding in Kanglong Chemical, with the Xinda Health China Mixed A Fund (003291) holding 959,400 shares, representing 5.41% of the fund's net value, making it the third-largest holding [2] - The fund has experienced a floating loss of approximately 1.5159 million yuan as of the latest data [2] Fund Manager Performance - The fund manager Li Junzhou has been in position for 165 days, with a total fund size of 634 million yuan and a best return of 11.17% during his tenure [3] - Yang Ke, another fund manager, has been in position for 5 years and 190 days, managing a total fund size of 1.324 billion yuan, with a best return of 43.77% during his tenure [3]

格隆汇11月17日丨根据联交所最新权益披露资料显示，2025年11月12日，康龙化成(03759.HK)获Norges Bank在场内以每股均价23.8072港元增持70.02万股，涉资约1667万港元。 | 芸植序线 | 大股東/董事/最高行政人員名 作出技擺的 買入 / 变出或涉及的 每股的平均價 | | | | 持有權益的股份數目 佔已發行的海關事件的日 相關法國股 債權證權益 | | --- | --- | --- | --- | --- | --- | | | | 原因 | 股份數目 | | ( 調金関上述*註 有投票權股期(日/月/ 份權益 | | | | | | | 份百分比 年) | | | | | | | ( 96 ) 日 1985 | | CS20251113E00453 Norges Bank | 700.200(L) | 1101(L) | | HKD 23.8072 | 18,270,424(L) 6.21(L)12/11/2025 | 增持后，Norges Bank最新持股数目为18,270,424股，持股比例由5.97%上升至6.21%。 ...